Wednesday, July 29, 2015

Roth upgrades IGI Labs to buy

Roth upgrades IGI Labs to buy

July 24, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded IGI Laboratories (NYSE MKT:IG) to “buy” from “neutral” and raised its price target to $11 from $7, saying 2016 could be a breakout year. The stock closed at $6.78 on Thursday. “The impetus for our upgrade is stabilization of the econazole nitrate franchise, a lower valuation, and potential ANDA […]

ROTH ups Titan Pharma price target to $1.50

ROTH ups Titan Pharma price target to $1.50

July 17, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on Titan Pharmaceuticals (OTCQB:TTNP) to $1.50 from $1.25. The stock closed at 80 cents on Thursday. Analyst Scott Henry writes that the driver for the increased price target is the positive Phase 3 data on Probuphine, which was reported last month. Probuphine is a six-month implant […]

Roth upgrades QLT to buy

Roth upgrades QLT to buy

June 9, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded QLT (NASDAQ:QLTI; TSX:QLT) to “buy” from “neutral” and raised its price target to $5.50 from $4.50, following the proposed acquisition of InSite Vision (OTC:INSV). The stock closed at $3.99 on Monday. “We believe that QLT’s financial resources could unlock the value in this emerging eye care company,” writes analyst […]

Roth starts Zosano Pharma at buy

Roth starts Zosano Pharma at buy

February 23, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Zosano Pharma (NASDAQ:ZSAN) with a “buy” rating and price target of $20. The stock closed at $11.09 on Friday. Zosano Pharma has a microneedle “patch” platform that provides injection-like results with a more tolerable delivery vehicle. “The impetus for our buy rating is the potential of the […]

Roth starts Titan Pharma at buy

Roth starts Titan Pharma at buy

January 20, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Titan Pharmaceuticals (OTCBB:TTNP) with a “buy” rating and a price target of $1.25. The stock closed at 47 cents on Monday. “The impetus for our buy rating is the potential of the company’s developmental Probuphine six-month implant of buprenorphine for the treatment of opioid dependence,” writes analyst […]

Roth starts NeuroDerm at buy

Roth starts NeuroDerm at buy

December 9, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of NeuroDerm (NASDAQ:NDRM) with a “buy” rating and $17.50 price target. The stock closed at $8.04 on Monday. “The impetus for our buy rating is the potential of the company’s new treatments for Parkinson’s disease (ND0612H and ND0612L) to improve efficacy and reduce side effects versus the current […]

Roth starts CorMedix at buy

Roth starts CorMedix at buy

July 24, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and $3 price target. The stock closed at $1.94 on Wednesday. “The impetus for our buy rating is the potential of the company’s Neutrolin compound to drive revenues and ultimately profits,” writes analyst Scott Henry. Neutrolin is approved in Europe and […]

Roth starts Kindred Biosciences at buy

Roth starts Kindred Biosciences at buy

February 4, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Kindred Biosciences (NYSE:KIN) with a “buy” rating and $20 price target. The stock closed at $15.41 on Monday.  Kindred is focused on developing and marketing new drugs for dogs, horses, and cats.  “The impetus for our buy rating is a low-risk animal health pipeline that could result […]

Roth ups Chelsea Therapeutics price target

Roth ups Chelsea Therapeutics price target

January 17, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” Chelsea Therapeutics (NASDAQ:CHTP) to $7 from $4, reflecting a positive FDA panel ruling for its Northera drug candidate. The stock closed at $4.70 on Thursday. On Tuesday, the FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16-1 to recommend approval of Northera for […]

Roth starts ANI Pharma at buy

Roth starts ANI Pharma at buy

January 7, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of ANI Pharmaceuticals (NASDAQ:ANIP) with a “buy” rating and $27 price target. The stock closed at $19 on Monday. “The impetus for our buy rating is continued earnings growth based on strong current revenue drivers, capacity for expansion, and a pipeline (internal and external) ready to fill that […]

Next Page »

Email Newsletters with Constant Contact
Google+